Inventor · disambiguated record
John Andrew Christopher
Also filed as: CHRISTOPHER JOHN · CHRISTOPHER JOHN ANDREW
23 granted patents·7 pending applications·74 citations·filing 2005–2025
95Inventor score
Files withHEPTARES THERAPEUTICS LTD22NXERA PHARMA UK LTD4CENTESSA PHARMACEUTICALS UK LTD2OREXIA THERAPEUTICS LTD1SMITHKLINE BEECHAM CORP1
Top patents by PatentIndex Score
30 records- 0196US11680053B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Jun 20, 2023·2 cites·22 claims
- 0296US11584732B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Feb 21, 2023·4 cites·17 claims
- 0396US10981889B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Apr 20, 2021·5 cites·12 claims
- 0493US10246432B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 2, 2019·9 cites·12 claims
- 0592US10584111B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Mar 10, 2020·7 cites·15 claims
- 0691US9676745B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Jun 13, 2017·10 cites·9 claims
- 0789US10166226B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·3 cites·16 claims
- 0889US9925178B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·4 cites·16 claims
- 0988US9808457B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Nov 7, 2017·6 cites·17 claims
- 1086US9688660B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 27, 2017·5 cites·13 claims
- 1185US12415795B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsNXERA PHARMA UK LTD·Filed 2023·Granted Sep 16, 2025·0 cites·10 claims
- 1284US9802935B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 31, 2017·4 cites·9 claims
- 1383US9555044B2Orexin receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jan 31, 2017·3 cites·10 claims
- 1481US10888561B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jan 12, 2021·2 cites·10 claims
- 1581US9850237B2Orexin receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Dec 26, 2017·2 cites·12 claims
- 1680US10300056B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 28, 2019·2 cites·19 claims
- 1780US9249160B2Orexin receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2013·Granted Feb 2, 2016·3 cites·15 claims
- 1878US10259812B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·2 cites·11 claims
- 1976US10316028B2Orexin receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Jun 11, 2019·1 cites·5 claims
- 2072US12178813B2CGRP receptor antagonistsNXERA PHARMA UK LTD·Filed 2020·Granted Dec 31, 2024·0 cites·22 claims
- 2165US12331029B2Orexin 1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2019·Granted Jun 17, 2025·0 cites·17 claims
- 2261US2024360175A1Peptide derivatives and related uses as orexin agonistsCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 2359US2024217930A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2458US2024083845A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2558US2024239744A12-(3-ethynylbenzyl)-substituted heterocycle derivatives and related usesOREXIA THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2653US12344621B2CGRP antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Jul 1, 2025·0 cites·31 claims
- 2752US12240825B2Oxexin 1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 4, 2025·0 cites·20 claims
- 2842US2025277001A1Peptide derivatives and related uses as orexin agonistsCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
- 2942US2021179578A1Ox1 antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
- 3039US2008269200A1Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 InhibitorsSMITHKLINE BEECHAM CORP·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Andrew Christopher files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →